Psychiatric adverse events during levetiracetam therapy
- 9 September 2003
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 61 (5) , 704-706
- https://doi.org/10.1212/01.wnl.0000078031.32904.0d
Abstract
The prevalence and psychopathologic features of psychiatric adverse events (PAE) in 517 patients taking levetiracetam (LEV) were investigated. Fifty-three (10.1%) patients developed PAE. A significant association was found with previous psychiatric history, history of febrile convulsions, and history of status epilepticus, whereas lamotrigine co-therapy had a protective effect. PAE were not related to the titration schedule of LEV, and certain patients seem to be biologically more vulnerable.Keywords
This publication has 9 references indexed in Scilit:
- Disease modification in partial epilepsyBrain, 2002
- Pyrrolidone derivativesThe Lancet, 2001
- Levetiracetam Psychosis in Children with EpilepsyEpilepsia, 2001
- A systematic review of the safety profile of levetiracetam: a new antiepileptic drugEpilepsy Research, 2001
- Long-term continuation of levetiracetam in patients with refractory epilepsyNeurology, 2001
- Efficacy and tolerability of 1000–4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsyEpilepsy Research, 2000
- Levetiracetam for partial seizuresNeurology, 2000
- Revisiting the Concept of Identifiable NeuronsBrain, Behavior and Evolution, 2000
- Proposal for Revised Classification of Epilepsies and Epileptic SyndromesEpilepsia, 1989